Physician profile

John P Duggan

Orthopaedic Surgery · Harker Heights, TX

NPI 1134396906

$6,515.08

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$558.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Pylant Medical $5,851.38 2020-2022
Axogen $172.43 2023-2024 Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector
Avita Medical Americas, LLC $151.88 2023 Recell
Miach Orthopaedics, INC. $147.80 2024
Stryker Corporation $86.31 2023 Mako
Bioventus LLC $53.46 2022
Smith+Nephew, INC. $25.63 2022
Pacira Therapeutics, INC. $14.62 2019
Convatec INC. $11.57 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John P Duggan

$6,515.08

in general payments reported 2019-2025

Years
2019-2024
Top company
Pylant Medical

https://glasscript.com/doctor/6972/john-p-duggan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.